[1] Williams CD,Stengel J,Asike MI,et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy:a prospective study. Gastroenterology,2011,140:124-131.
[2] Wong VW,Chu WC,Wong GL,et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese:a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut,2011,[Epub ahead of print].
[3] Wong VW,Wong GL,Chu WC,et al. Hepatitis B virus infection and fatty liver in the general population. J Hepatol,2011, [Epub ahead of print]
[4] Ayonrinde OT,Olynyk JK,Beilin LJ,et al. Gender-specific differences in adipose distribution and adipocytokines influence adolescent nonalcoholic fatty liver disease. Hepatology,2011,53:800-809.
[5] Santoro N,Zhang CK,Zhao H,et al. A variant in the glucokinase regulatory protein（GCKR）gene is associated with fatty liver in obese children and adolescents. Hepatology,2011,[Epub ahead of print]
[6] Lomonaco R,Ortiz-Lopez C,Orsak B,et al. Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis. Hepatology,2011,[Epub ahead of print]
[7] Bambha K,Belt P,Abraham M,et al. Ethnicity and nonalcoholic fatty liver disease. Hepatology,2011,[Epub ahead of print]
[8] Sookoian S,Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene （PNPLA3） on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology,2011,53:1883-1894.
[9] Al-Serri A,Anstee QM,Valenti L,et al. The SOD2 C47T polymorphism influences NAFLD fibrosis severity:Evidence from case-control and intra-familial allele association studies. J Hepatol,2011. [Epub ahead of print]
[10] Molloy JW,Calcagno CJ,Williams CD,et al. Association of coffee and caffeine consumption with fatty liver disease,non-alcoholic steatohepatitis,and degree of hepatic fibrosis. Hepatology,2011,[Epub ahead of print]
[11] Aron-Wisnewsky J,Minville C,Tordjman J,et al. Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. J Hepatol,2011,[Epub ahead of print]
[12] Lemoine M,Serfaty L. Chronic intermittent hypoxia:A breath of fresh air in the understanding of NAFLD pathogenesis. J Hepatol,2011,[Epub ahead of print].
[13] Nelson JE,Wilson L,Brunt EM,et al. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology,2011,53:448-457.
[14] Charlton MR,Burns JM,Pedersen RA,et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology,2011,141:1249-1253.
[15] Younossi ZM,Stepanova M,Rafiq N,et al. Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortality. Hepatology,2011,53:1874-1882.
[16] Wong VW,Wong GL,Tsang SW,et al. High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut,2011,60:829-836.
[17] Palmeri ML,Wang MH,Rouze NC,et al. Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. J Hepatol,2011,55:666-672.
[18] Pihlajamaki J,Kuulasmaa T,Kaminska D,et al. Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans. J Hepatol,2011,[Epub ahead of print]
[19] Joka D,Wahl K,Moeller S,et al. Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology,2011,[Epub ahead of print]
[20] Sanyal AJ,Brunt EM,Kleiner DE,et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology,2011,54:344-353. |
